[go: up one dir, main page]

FR2962437B1 - Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique - Google Patents

Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Info

Publication number
FR2962437B1
FR2962437B1 FR1055475A FR1055475A FR2962437B1 FR 2962437 B1 FR2962437 B1 FR 2962437B1 FR 1055475 A FR1055475 A FR 1055475A FR 1055475 A FR1055475 A FR 1055475A FR 2962437 B1 FR2962437 B1 FR 2962437B1
Authority
FR
France
Prior art keywords
preparing
therapeutic application
imidazopyridine derivatives
imidazopyridine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1055475A
Other languages
English (en)
Other versions
FR2962437A1 (fr
Inventor
Chantal Alcouffe
Reinhard Kirsch
Corentin Herbert
Gilbert Lassale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2962437(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1055475A priority Critical patent/FR2962437B1/fr
Priority to EP11743633.7A priority patent/EP2590976B1/fr
Priority to PH1/2013/500041A priority patent/PH12013500041A1/en
Priority to AU2011275427A priority patent/AU2011275427B2/en
Priority to PCT/IB2011/052954 priority patent/WO2012004732A1/fr
Priority to PL11743633T priority patent/PL2590976T3/pl
Priority to EA201291414A priority patent/EA022690B1/ru
Priority to CA2804915A priority patent/CA2804915C/fr
Priority to NZ604973A priority patent/NZ604973A/en
Priority to MA35637A priority patent/MA34450B1/fr
Priority to CN201180042933.1A priority patent/CN103080111B/zh
Priority to HRP20151309TT priority patent/HRP20151309T1/hr
Priority to PT117436337T priority patent/PT2590976E/pt
Priority to JP2013517656A priority patent/JP5889295B2/ja
Priority to BR112013000273-5A priority patent/BR112013000273B1/pt
Priority to DK11743633.7T priority patent/DK2590976T3/en
Priority to ES11743633.7T priority patent/ES2556754T3/es
Priority to KR1020137002987A priority patent/KR101820548B1/ko
Priority to HUE11743633A priority patent/HUE025639T2/en
Priority to SI201130684T priority patent/SI2590976T1/sl
Priority to US13/808,503 priority patent/US8759344B2/en
Priority to PE2013000005A priority patent/PE20130651A1/es
Priority to SG2012093464A priority patent/SG186396A1/en
Priority to MX2012015120A priority patent/MX2012015120A/es
Priority to ARP110102398A priority patent/AR082112A1/es
Priority to UY0001033488A priority patent/UY33488A/es
Priority to TW100123929A priority patent/TWI520961B/zh
Publication of FR2962437A1 publication Critical patent/FR2962437A1/fr
Application granted granted Critical
Publication of FR2962437B1 publication Critical patent/FR2962437B1/fr
Priority to CR20120643A priority patent/CR20120643A/es
Priority to TNP2012000608A priority patent/TN2012000608A1/en
Priority to ZA2012/09632A priority patent/ZA201209632B/en
Priority to GT201200346A priority patent/GT201200346A/es
Priority to NI201200192A priority patent/NI201200192A/es
Priority to IL223832A priority patent/IL223832A/en
Priority to CL2013000016A priority patent/CL2013000016A1/es
Priority to ECSP13012363 priority patent/ECSP13012363A/es
Priority to CO13001348A priority patent/CO6650360A2/es
Priority to US14/267,272 priority patent/US9452164B2/en
Priority to CY20151101146T priority patent/CY1117374T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR1055475A 2010-07-06 2010-07-06 Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique Expired - Fee Related FR2962437B1 (fr)

Priority Applications (38)

Application Number Priority Date Filing Date Title
FR1055475A FR2962437B1 (fr) 2010-07-06 2010-07-06 Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US13/808,503 US8759344B2 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof
PE2013000005A PE20130651A1 (es) 2010-07-06 2011-07-04 Derivados de imidazopiridina y su procedimiento de preparacion
MX2012015120A MX2012015120A (es) 2010-07-06 2011-07-04 Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica.
PCT/IB2011/052954 WO2012004732A1 (fr) 2010-07-06 2011-07-04 Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
PL11743633T PL2590976T3 (pl) 2010-07-06 2011-07-04 Pochodne imidazopirydyny, sposób ich wytwarzania i ich zastosowanie terapeutyczne
EA201291414A EA022690B1 (ru) 2010-07-06 2011-07-04 Имидазопиридиновые производные, способ их получения и терапевтическое использование
CA2804915A CA2804915C (fr) 2010-07-06 2011-07-04 Derives de l'imidazopyridine, procede pour leur preparation, et leur utilisation therapeutique
NZ604973A NZ604973A (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
MA35637A MA34450B1 (fr) 2010-07-06 2011-07-04 Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
CN201180042933.1A CN103080111B (zh) 2010-07-06 2011-07-04 咪唑并吡啶衍生物、其制备方法及其治疗用途
HRP20151309TT HRP20151309T1 (hr) 2010-07-06 2011-07-04 Derivati imidazopiridina, postupak za njihovu pripravu i njihova terapeutska upotreba
PT117436337T PT2590976E (pt) 2010-07-06 2011-07-04 Derivados da imidazopiridina, seu processo de preparação e sua utilização terapêutica
JP2013517656A JP5889295B2 (ja) 2010-07-06 2011-07-04 イミダゾピリジン誘導体、それらを調製するための方法およびそれらの治療上の使用
BR112013000273-5A BR112013000273B1 (pt) 2010-07-06 2011-07-04 Compostos derivados de imidazopiridina, processo para a preparação dos mesmos e uso terapêutico dos mesmos
DK11743633.7T DK2590976T3 (en) 2010-07-06 2011-07-04 Imidazopyridine, MANUFACTURING METHOD THEREOF AND THERAPEUTIC USE THEREOF
ES11743633.7T ES2556754T3 (es) 2010-07-06 2011-07-04 Derivados de imidazopiridina, procedimiento para la preparación de los mismos y uso terapéutico de los mismos
KR1020137002987A KR101820548B1 (ko) 2010-07-06 2011-07-04 이미다조피리딘 유도체, 그의 제조 방법 및 그의 치료 용도
HUE11743633A HUE025639T2 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, a process for their preparation and their therapeutic use
SI201130684T SI2590976T1 (sl) 2010-07-06 2011-07-04 Derivati imidazopiridina, postopek njihove priprave in njihova terapevtska uporaba
EP11743633.7A EP2590976B1 (fr) 2010-07-06 2011-07-04 Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
SG2012093464A SG186396A1 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
PH1/2013/500041A PH12013500041A1 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
AU2011275427A AU2011275427B2 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ARP110102398A AR082112A1 (es) 2010-07-06 2011-07-05 Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
UY0001033488A UY33488A (es) 2010-07-06 2011-07-06 Derivados de imidazopiridina, su procedimiento y preparacion y su aplicacion en terapeutica
TW100123929A TWI520961B (zh) 2010-07-06 2011-07-06 咪唑并吡啶衍生物、其製造方法及其治療用途
CR20120643A CR20120643A (es) 2010-07-06 2012-12-17 Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
TNP2012000608A TN2012000608A1 (en) 2010-07-06 2012-12-19 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ZA2012/09632A ZA201209632B (en) 2010-07-06 2012-12-19 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
GT201200346A GT201200346A (es) 2010-07-06 2012-12-20 Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
NI201200192A NI201200192A (es) 2010-07-06 2012-12-20 Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
IL223832A IL223832A (en) 2010-07-06 2012-12-24 History of imidazopyridine, process for their preparation and medical use
ECSP13012363 ECSP13012363A (es) 2010-07-06 2013-01-03 Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica
CL2013000016A CL2013000016A1 (es) 2010-07-06 2013-01-03 Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CO13001348A CO6650360A2 (es) 2010-07-06 2013-01-04 Derivados de imidazopiridina, su procedimiento de preparació;n y su aplicación en terapéutica
US14/267,272 US9452164B2 (en) 2010-07-06 2014-05-01 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof
CY20151101146T CY1117374T1 (el) 2010-07-06 2015-12-15 Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055475A FR2962437B1 (fr) 2010-07-06 2010-07-06 Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2962437A1 FR2962437A1 (fr) 2012-01-13
FR2962437B1 true FR2962437B1 (fr) 2012-08-17

Family

ID=43383651

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1055475A Expired - Fee Related FR2962437B1 (fr) 2010-07-06 2010-07-06 Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Country Status (37)

Country Link
US (2) US8759344B2 (fr)
EP (1) EP2590976B1 (fr)
JP (1) JP5889295B2 (fr)
KR (1) KR101820548B1 (fr)
CN (1) CN103080111B (fr)
AR (1) AR082112A1 (fr)
AU (1) AU2011275427B2 (fr)
BR (1) BR112013000273B1 (fr)
CA (1) CA2804915C (fr)
CL (1) CL2013000016A1 (fr)
CO (1) CO6650360A2 (fr)
CR (1) CR20120643A (fr)
CY (1) CY1117374T1 (fr)
DK (1) DK2590976T3 (fr)
EA (1) EA022690B1 (fr)
EC (1) ECSP13012363A (fr)
ES (1) ES2556754T3 (fr)
FR (1) FR2962437B1 (fr)
GT (1) GT201200346A (fr)
HR (1) HRP20151309T1 (fr)
HU (1) HUE025639T2 (fr)
IL (1) IL223832A (fr)
MA (1) MA34450B1 (fr)
MX (1) MX2012015120A (fr)
NI (1) NI201200192A (fr)
NZ (1) NZ604973A (fr)
PE (1) PE20130651A1 (fr)
PH (1) PH12013500041A1 (fr)
PL (1) PL2590976T3 (fr)
PT (1) PT2590976E (fr)
SG (1) SG186396A1 (fr)
SI (1) SI2590976T1 (fr)
TN (1) TN2012000608A1 (fr)
TW (1) TWI520961B (fr)
UY (1) UY33488A (fr)
WO (1) WO2012004732A1 (fr)
ZA (1) ZA201209632B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
DK2861595T5 (en) 2012-06-13 2018-01-15 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
JP2016534139A (ja) * 2013-09-11 2016-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのケト−イミダゾピリジン誘導体
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
RU2712222C2 (ru) 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
US9640143B1 (en) * 2016-01-22 2017-05-02 Sony Corporation Active video projection screen coordinating grayscale values of screen with color pixels projected onto screen
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114380752A (zh) * 2020-10-22 2022-04-22 南开大学 一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN114016060B (zh) * 2021-11-23 2023-05-02 南昌大学 一种酚类化合物的合成方法
CN115978796B (zh) * 2022-12-26 2025-03-07 烟台宁远药业有限公司 取代含氮喹唑啉酮类化合物的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
FR2838123B1 (fr) 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
ATE500254T1 (de) 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
FR2865934B1 (fr) 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
US20090042820A1 (en) * 2004-11-22 2009-02-12 Threshold Pharmaceuticals, Inc. Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
CN1733742A (zh) * 2005-07-12 2006-02-15 浙江大学 苯并三嗪衍生物的制备及用途
FR2893616B1 (fr) 2005-11-23 2008-01-04 Sanofi Aventis Sa Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (fr) 2006-07-24 2008-02-27 Sanofi-Aventis Utilisation de dérivés de indolizines, inhibiteurs de FGF, pour la préparation d'un médicament pour le traitement d'affections dégénératives des articulations
CN1887878A (zh) * 2006-07-26 2007-01-03 浙江大学 三嗪氮氧化物及合成方法和用途
WO2008085302A1 (fr) * 2006-12-20 2008-07-17 Merck & Co., Inc. Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
CN101239978A (zh) 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
WO2011055320A1 (fr) 2009-11-06 2011-05-12 Piramal Life Sciences Limited Dérivés d'imidazopyridine
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
DK2590976T3 (en) 2015-12-21
MA34450B1 (fr) 2013-08-01
MX2012015120A (es) 2013-05-01
AU2011275427B2 (en) 2016-04-21
ES2556754T3 (es) 2016-01-20
ZA201209632B (en) 2014-03-26
HRP20151309T1 (hr) 2016-01-01
KR101820548B1 (ko) 2018-01-19
US20140243328A1 (en) 2014-08-28
HUE025639T2 (en) 2016-04-28
GT201200346A (es) 2014-05-20
CY1117374T1 (el) 2017-04-26
BR112013000273A2 (pt) 2017-10-31
BR112013000273A8 (pt) 2018-04-24
TN2012000608A1 (en) 2014-04-01
FR2962437A1 (fr) 2012-01-13
NI201200192A (es) 2013-05-13
BR112013000273B1 (pt) 2020-09-29
JP5889295B2 (ja) 2016-03-22
CL2013000016A1 (es) 2013-04-19
EA022690B1 (ru) 2016-02-29
CR20120643A (es) 2013-02-05
PT2590976E (pt) 2016-01-20
CA2804915A1 (fr) 2012-01-12
CA2804915C (fr) 2018-07-03
UY33488A (es) 2012-01-31
SI2590976T1 (sl) 2016-01-29
CN103080111B (zh) 2016-06-15
WO2012004732A1 (fr) 2012-01-12
JP2013530211A (ja) 2013-07-25
EP2590976A1 (fr) 2013-05-15
SG186396A1 (en) 2013-01-30
EA201291414A1 (ru) 2013-05-30
NZ604973A (en) 2014-05-30
US8759344B2 (en) 2014-06-24
CN103080111A (zh) 2013-05-01
IL223832A (en) 2017-03-30
TWI520961B (zh) 2016-02-11
PH12013500041A1 (en) 2017-08-23
AR082112A1 (es) 2012-11-14
PL2590976T3 (pl) 2016-03-31
ECSP13012363A (es) 2013-01-31
EP2590976B1 (fr) 2015-09-16
PE20130651A1 (es) 2013-06-20
KR20130128363A (ko) 2013-11-26
TW201217370A (en) 2012-05-01
US20130116250A1 (en) 2013-05-09
CO6650360A2 (es) 2013-04-15
AU2011275427A1 (en) 2013-01-24
US9452164B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
FR2962437B1 (fr) Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) Derives d'indolizines, procedes de preparation et application en therapeutique
FR2986002B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2958291B1 (fr) Procede de preparation de derives d'amino-benzofurane
IL232906A0 (en) Pyrazolopyridine derivatives, a process for their preparation and their medical use
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2949465B1 (fr) Derives chromones, leur procede de preparation et leurs applications therapeutiques
SG11201400092VA (en) Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
FR2955109B1 (fr) Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2943057B1 (fr) DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES
FR2998892B1 (fr) Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
FR2986232B1 (fr) Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
FR2980136B1 (fr) Composites, leur procede de preparation et les voiles de vol les comprenant
FR2941946B1 (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2953837B1 (fr) Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2944013B1 (fr) Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
EP2789604A4 (fr) Dérivé de daidzéine, sel de qualité pharmaceutique et procédé de fabrication de ce dérivé, et composition pharmaceutique contenant ledit dérivé

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20170331